Global Risk Management in Patients with Type 2 Diabetes Mellitus.
From: Rush University Medical Center, Chicago, Illinois 60612, USA. michaeldavidson@radiantresearch.com
The American journal of cardiology
- Publish Date: Feb 2007
- ISSN: 0002-9149
- Volume: 99
- Issue: 4A
- Pages: 41B-50B
- Medium: Print
- Language: English
- Citation (JAMA): Davidson Michael H, et al. Global Risk Management in Patients with Type 2 Diabetes Mellitus.. Am. J. Cardiol. Feb 2007;99:41B-50B
Abstract
It is well established that aggressive risk factor modification results in improved cardiovascular disease (CVD) outcomes. Yet, patients with type 2 diabetes mellitus have a much higher baseline risk for cardiovascular events. As type 2 diabetes and hypertension commonly coexist, achieving recommended targets for diabetes, hypertension, and CVD requires aggressive management. Global risk reduction with aggressive low-density lipoprotein reduction and through the additional normalization of glucose levels and blood pressure can help to reduce absolute risk in this very high-risk population.
Mesh Headings (Keywords): Algorithms, Apolipoproteins B, Blood Glucose, C-Reactive Protein, Cardiovascular Diseases, Cholesterol, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypertension, Hypoglycemic Agents, Peptide Fragments, Risk Factors
Check for Full Text / PubMed Unique Identifier (PMID): 17307057
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.